Acadia Pharmaceuticals (ACAD) Stock: Here’s What You Need To Know!

Acadia Pharmaceuticals (NASDAQ:ACAD) On Monday, Acadia Pharmaceuticals announced that it had initiated a phase 2 trial in patients with Alzheimer’s Disease Agitation. Once again ACAD will use its drug Pimavanserin to see if the drug will work in this targeted indication. The company has already received FDA approval for Pimavanserin in Parkinson’s Disease Psychosis. Now … Read more